Hildegarde Paz-Díaz

Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.

G. Sawicki, R. Fischer, C. Owen, 2021, The Lancet. Respiratory medicine.

Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPD

B. Celli, V. Pinto-Plata, L. Torre-Bouscoulet, 2008, European Respiratory Journal.

Pulmonary Rehabilitation Improves Depression, Anxiety, Dyspnea and Health Status in Patients with COPD

B. Celli, M. Montes de Oca, H. Paz-Díaz, 2007, American journal of physical medicine & rehabilitation.

A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant.

G. Sawicki, C. Wainwright, I. Sermet-Gaudelus, 2022, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR

M. Rosenfeld, S. McColley, M. Higgins, 2022, American journal of respiratory and critical care medicine.